World's Best Scientists 2026 revealed!
Diane Provencher

Diane Provencher

D-Index & Metrics

Medicine

D-Index
74
Citations
25181
World Ranking
19315
National Ranking
817

Diane Provencher publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Diane Provencher sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 335 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Diane Provencher D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Diane Provencher sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 74 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Diane Provencher is affiliated with the University of Montreal in Canada and has a research focus predominantly in Medicine and Biochemistry, Genetics, and Molecular Biology. Their work spans several key subfields including Oncology, Reproductive Medicine, Molecular Biology, Genetics, and Immunology.

The scientist's research topics are primarily centered on ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, endometrial and cervical cancer treatments, cancer immunotherapy and biomarkers, CRISPR and genetic engineering, and sarcoma diagnosis and treatment.

Frequent co-authors of Diane Provencher include Anne-Marie Mes-Masson, David M. O'Malley, Amit M. Oza, Ana Oaknin, and Lucy Gilbert.

The main publication venues for their research have been:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • International Journal of Gynecological Cancer
  • Scientific Reports

Among the recent papers authored or co-authored by Diane Provencher are:

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial (2021, The Lancet Oncology)
  • A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45) (2022, Journal of Clinical Oncology)
  • Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial (2023, Journal of Clinical Oncology)
  • Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) (2021, Nature Communications)
  • Uterine serous carcinoma (2021, Gynecologic Oncology)

Best Publications

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • ARID1A mutations in endometriosis-associated ovarian carcinomas.

    Kimberly C. Wiegand;Sohrab P. Shah;Osama M. Al-Agha;Yongjun Zhao

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Oral Contraceptives and the Risk of Hereditary Ovarian Cancer

    S. A. Narod;H. Risch;R. Moslehi;A. Dorum

  • Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary

    Sohrab P Shah;Martin Köbel;Janine Senz;Ryan D Morin

  • 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

    A du Bois;M Quinn;T Thigpen;J Vermorken

  • Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

    Stephanie M. de Boer;Melanie E. Powell;Linda Mileshkin;Dionyssios Katsaros

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

    Stephanie M de Boer;Melanie E Powell;Linda Mileshkin;Dionyssios Katsaros

  • Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

    Amit M. Oza;Laurie Elit;Ming-Sound Tsao;Suzanne Kamel-Reid

  • Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

    Bradley J. Monk;Andrés Poveda;Ignace Vergote;Francesco Raspagliesi

  • Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

    Amit M. Oza;Anna V. Tinker;Ana Oaknin;Ronnie Shapira-Frommer

  • Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.

    te Nienke Grootenhuis;van der Ate Zee;H. C. van Doorn;J. van der Velden

  • Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes

    Yi Kan Wang;Ali Bashashati;Michael S Anglesio;Dawn R Cochrane

  • Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC).

    Magdalena Zietarska;Christine M. Maugard;Christine M. Maugard;Abdelali Filali-Mouhim;Mona Alam-Fahmy

  • CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

    Martin Turcotte;Kathleen Spring;Sandra Pommey;Guillaume Chouinard

  • Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

    Beth Y. Karlan;Amit M. Oza;Gary E. Richardson;Diane M. Provencher

  • Clinical trials in recurrent ovarian cancer.

    Michael Friedlander;Edward Trimble;Anna Tinker;David Alberts

  • CHARACTERIZATION OF FOUR NOVEL EPITHELIAL OVARIAN CANCER CELL LINES

    D. M. Provencher;H. Lounis;L. Champoux;M. Tétrault

  • An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.

    Martin Köbel;Kurosh Rahimi;Peter F. Rambau;Christopher Naugler;Christopher Naugler

Frequent Co-Authors

Patricia N. Tonin
Patricia N. Tonin McGill University
Anne-Marie Mes-Masson
Anne-Marie Mes-Masson University of Montreal
William D. Foulkes
William D. Foulkes McGill University
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Steven A. Narod
Steven A. Narod University of Toronto
Martin Köbel
Martin Köbel University of Calgary
Ursula A. Matulonis
Ursula A. Matulonis Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Prospective medical professionals have a wide range of online academic pathways to launch or advance their careers in healthcare. Many students start by comparing the phd nursing programs offered online, which are ideal for those interested in research, teaching, or high-level clinical roles.

For registered nurses intending to elevate their credentials, exploring the cheapest accredited online rn to bsn programs can make earning a bachelor's degree accessible and affordable. These programs often offer flexible schedules for busy healthcare professionals.

Those without a nursing background but eager to make a direct entry into the field should consider entry level msn programs online. Such options are designed for non-nurses seeking a fast-track into advanced nursing careers.

If cost or admissions requirements are concerns, students can look for the easiest bsn program to get into. These programs can provide more accessible entry points into nursing and help address the ongoing demand for qualified professionals in the field.

Best Scientists Citing Diane Provencher

Trending Scientists